Zealand Pharma has patented a method for producing acylated glucagon analogue peptides for treating obesity, diabetes, and metabolic disorders. The compound formula includes specific peptide sequences and fatty chain conjugates, enhancing selectivity for the GLP-1 receptor. GlobalData’s report on Zealand Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zealand Pharma, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Zealand Pharma's grant share as of February 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11884713B2) discloses a method for producing a compound with a specific chemical formula. The compound consists of a peptide sequence with defined amino acid residues and a unique residue denoted as ?. This ? residue is conjugated to a substituent with a specific structure, including a fatty chain with a polar group and a connection to another group at the end of the chain. The polar group can be a carboxylic acid or its bioisostere, a phosphonic acid, or a sulfonic acid group. The method involves modifying a precursor peptide to introduce this substituent at the designated residue ?, resulting in the formation of the desired compound.
Furthermore, the patent also includes additional claims specifying the compound produced by the method described, emphasizing the unique structure and composition of the compound. The method outlined in the patent aims to provide a systematic approach to synthesizing compounds with specific characteristics and functionalities, particularly focusing on the incorporation of the ? residue and its conjugation to the defined substituent. By detailing the peptide sequence, amino acid residues, and the structural requirements for the substituent, the patent offers a comprehensive guide for producing these compounds efficiently and accurately. The claims within the patent highlight the novelty and specificity of the method, underscoring its potential applications in various fields requiring compounds with the specified formula and properties.
To know more about GlobalData’s detailed insights on Zealand Pharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
